Rare Diseases
From the Journals
Autoantibody against enteric nervous system protein linked to GI dysfunction in systemic sclerosis
If validated as a biomarker, antigephyrin autoantibodies could help identify patients at higher risk for GI symptoms like constipation.
Clinical Review
Brachioradial Pruritus: An Etiologic Review and Treatment Summary
This article reviews previously trialed conservative management options, including chiropractic manipulation, acupuncture, physiotherapy, and...
Latest News
Study evaluating in utero treatment for hypohidrotic ectodermal dysplasia seeks enrollees
Researchers are seeking to enroll mothers 18 years of age and older who are genetically confirmed carriers of the XLEHD mutation and pregnant with...
Latest News
Progress seen on five fronts for substantially improving treatment of epidermolysis bullosa
Progress on multiple fronts for control of disease or its symptoms suggests “we are on the cusp of a new era.”
Latest News
Case report describes pediatric RIME triggered by norovirus
The study author says the incidence of RIME appears to be increasing, although its true epidemiology is unknown.
Feature
Camp Discovery: A place for children to be comfortable in their own skin
Chronic skin conditions carry a heavy psychological burden, but a special 1-week camp for youth 8-16 founded 30 years ago aims to lift that weight...
Latest News
New guidelines for MTX use in pediatric inflammatory skin disease unveiled
One of the recommendations states that liver biopsy is not indicated for routine monitoring of pediatric patients taking low-dose MTX.
News from the FDA/CDC
FDA approves ritlecitinib for ages 12 and up for alopecia areata
It is the second JAK inhibitor approved for treating alopecia areata, following approval of baricitinib (Olumiant) in June 2022 for alopecia...
Conference Coverage
EULAR systemic sclerosis recommendations now include immunosuppressants
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
Latest News
Scientists discover variants, therapy for disabling pansclerotic morphea
The JAK inhibitor ruxolitinib dramatically improved wound healing and rashes in patients with the very rare disorder.
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.